Mumps IgG capture EIA: Cat. No: MuVG012

Intended use:

For the detection of mumps specific IgG antibodies in human oral fluid samples.

Test Principle

In the Microimmune Mumps IgG capture EIA recombinant mumps nucleoprotein (rMuNP) antigen is added to anti-human IgG coated microtitre wells. This is followed by the addition of undiluted oral fluid extracted from a collection device(e.g. "Oracol" or "OraSure") or diluted serum / plasma. Mumps specific IgG in the specimen if present binds to the anti-human IgG coated microwell.the well and to the rMuNP. After washing the wells, a monoclonal antibody to the rMuNP, conjugated to horseradish peroxidase is added. After washing, tetramethylbenzadine (TMB) substrate is added. The presence of mumps specific IgG in the sample results in a colour change in the TMB from colourless to blue. The enzymatic reaction is terminated with acid which causes a further change in colour from blue to yellow. The colour change and intensity is monitored using a spectrophotometric plate reader set at 450nm with a correction filter between 620 and 650nm. The presence of mumps specific IgM is indicated by optical density values above the cut-off.

Features of the test:

• Assay time:2h
• Specimen type: oral fluid, serum / plasma
• Reagents: Colour coded and mostly ready to use.
• Shelf life: 12 months at 2..8°C
• *Sensitivity of the Microimmune Mumps IgM capture EIA on serum samples compared to two competitor tests was 100% (95% CI 95.7% to100.0%) for test 1and 94.3% (95% CI 88.1% to 97.9%) for test 2.
• *Specificity of MI test on serum samples compared to competitior test 1: was 94.2% (95% CI 84.1.13 to 98.9).

*A detailed description of the evaluation of the test is given in the product insert.

Status: To be launched September 2004.

Discounts on bulk purchases.  Please contact us directly by fax/ e-mail or phone for further information.